BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines external R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23) ($M)
Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS)
Latest, FY2023
77.7
Period ended Dec 31, 2023
Change on a year earlier
-27.1%
107 in FY2022
History
4 years
Since FY2020
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 77.7 | -27.1% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2022 | Dec 31, 2022 | 107 | +63.8% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2021 | Dec 31, 2021 | 65.1 | +194.1% | 8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗ |
| FY2020 | Dec 31, 2020 | 22.1 | – | 8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23) ($M), annual FY2020–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_mol_ociperlimab
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.